Somatic mutations in FGFR2 are present in 4% to 5% of patients diagnosed with non–small
cell lung cancer (NSCLC). Amplification and mutations in FGFR genes have been identified
in patients with NSCLCs, and clinical trials are testing the efficacy of anti-FGFR therapies.
FGFR2 and other FGFR kinase family gene alterations have been found in both lung
squamous cell carcinoma and lung adenocarcinoma, although mouse models of FGFR-
driven lung cancers have not been reported. Here, we generated a genetically engineered …

Abstract Somatic mutations in Fibroblast Growth Factor Receptor 2 (FGFR2) have been
found in 4-5% of patients diagnosed with non-small cell lung cancer (NSCLC). FGFR2 and
other FGFR kinase family gene alterations have been found in lung squamous cell
carcinoma, adenocarcinoma, and other malignancies though mouse models of FGFR driven
lung cancers have not been reported. Here, we generated a genetically engineered mouse
model (GEMM) of NSCLC driven by a kinase domain mutation in FGFR2. Combined with …